MeSH D058729 - peripheral arterial disease
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D058729:
Peripheral arterial disease
D000089802:Chronic limb-threatening ischemia
0 Companies
0 Drugs
Success rate
D007383:Intermittent claudication
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Merck Sharp & Dohme | Vorapaxar | Zontivity | 2015-01-19 | |||
| Accord Healthcare | Rivaroxaban | Rivaroxaban Accord | 2020-11-16 | |||
| Key Therapeutics | Vorapaxar | Zontivity | 2024-05-30 | 2014-05-08 | ||
| Mylan | Rivaroxaban | Rivaroxaban Viatris (previously Rivaroxaban Mylan) | 2021-11-12 |
Clinical Trials
Historical Success Rate
Phase 1
53%16/30
Phase 2
50%21/42
Phase 3
48%14/29
Approved: 2Overall Success rate: 13%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use